Literature DB >> 23989016

Norovirus in immunocompromised patients.

Jill Atmar1, Ellen Mullen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23989016     DOI: 10.1188/13.ONF.434-436

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


× No keyword cloud information.
  5 in total

Review 1.  Burden of norovirus in healthcare facilities and strategies for outbreak control.

Authors:  A Kambhampati; M Koopmans; B A Lopman
Journal:  J Hosp Infect       Date:  2015-02-04       Impact factor: 3.926

2.  Norovirus Loads in Stool Specimens of Cancer Patients with Norovirus Gastroenteritis.

Authors:  Taojun He; Tracy A McMillen; Yuanyuan Qiu; Liang Hua Chen; Xuedong Lu; Xiao-Li Pang; Mini Kamboj; Yi-Wei Tang
Journal:  J Mol Diagn       Date:  2017-08-12       Impact factor: 5.568

3.  Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication.

Authors:  Wen Dang; Yuebang Yin; Yijin Wang; Wenshi Wang; Junhong Su; Dave Sprengers; Luc J W van der Laan; Krzysztof Felczak; Krzysztof W Pankiewicz; Kyeong-Ok Chang; Marion P G Koopmans; Herold J Metselaar; Maikel P Peppelenbosch; Qiuwei Pan
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  Complicated norovirus infection and assessment of severity by a modified Vesikari disease score system in hospitalized children.

Authors:  Pei-Lin Wang; Shih-Yen Chen; Chi-Neu Tsai; Hsun-Ching Chao; Ming-Wei Lai; Yi-Jung Chang; Chyi-Liang Chen; Cheng-Hsun Chiu
Journal:  BMC Pediatr       Date:  2016-10-05       Impact factor: 2.125

Review 5.  Norovirus Vaccine: Priorities for Future Research and Development.

Authors:  Susanna Esposito; Nicola Principi
Journal:  Front Immunol       Date:  2020-07-07       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.